Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are use...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English |
Published |
22.04.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed. |
---|---|
Bibliography: | Application Number: US201113069326 |